Exploring new targets and mechanisms in Alzheimer's disease
Official title: Harnessing new targets and mechanisms mediating AD pathogenesis
Funded at University of Florida · NIH-10980533 · Data updated 2026-11-12
This study is looking at how two proteins, amyloid beta and tau, work together in Alzheimer's disease, using a special fly model to help find new ways to understand and treat the condition, which could eventually help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $343,125 |
| NIH project number | 5R01AG077534-03 |
| Project ID | NIH-10980533 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with early cognitive decline.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to amyloid or tau pathology may not benefit from this research.
What this research studies
This research investigates the complex interactions between amyloid beta-42 and tau proteins in Alzheimer's disease, which are known to contribute to cognitive decline and memory loss. Using a novel fly model that produces both human amyloid beta and tau, the study aims to uncover how these proteins work together to drive disease progression. By conducting a large-scale genetic screen, researchers are identifying genes that may influence the pathology of Alzheimer's, potentially leading to new therapeutic targets. Patients may benefit from insights gained into the mechanisms of Alzheimer's, which could inform future treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets for treating Alzheimer's disease, potentially improving outcomes for patients.
How similar studies have gone: Previous research has shown promise in targeting amyloid and tau interactions, suggesting that this approach could yield significant insights into Alzheimer's disease mechanisms.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Rincon-Limas, Diego E — University of Florida
- Study coordinator: Rincon-Limas, Diego E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.